TECHNOLOGY
As US measles cases rise, biotech firms start developing new treatments
Ars TechnicaTuesday, July 28, 2026 at 1:32 PM
RedScroll Brief
The US is making measles great again, so treatment options are needed for the most vulnerable.
Desk copy
RedScroll Briefing
Extractive editorial brief — not a reprint of the original
What happened
The US is making measles great again, so treatment options are needed for the most vulnerable.
Why it matters
Technology shifts change how people work, communicate, and build — often faster than policy can follow.
Background
Ars Technica reported on this under technology. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.
Timeline
Ars Technica published: As US measles cases rise, biotech firms start developing new treatments
Story is in today’s RedScroll edition. Follow the original source for updates.
Economic impact
Secondary effects may show up in markets and supply chains linked to Measles and Cases.
More on
Related stories
- Investors cool on Europe’s old-style defence firms
The Economist BusinessBUSINESS
- Ticket prices set to rise by 15p as Heathrow able to recover runway project money
BBC BusinessBUSINESS
- The Download: OpenAI’s predictable hack, and an AI stock sell-off
MIT Technology ReviewTECHNOLOGY
- How lasers could help provide fuel for nuclear reactors
MIT Technology ReviewTECHNOLOGY
- The Download: lasers for nuclear fuel, and organ preservation advances
MIT Technology ReviewTECHNOLOGY
- Audi has a new flagship designed with the US in mind: The 2027 Q9
Ars TechnicaTECHNOLOGY
Sources
Ars Technica — original reporting. RedScroll provides an extractive briefing only.